Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CNST NASDAQ:KNSA NASDAQ:OMER NASDAQ:PLRX NASDAQ:ZGNX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNSTConstellation Pharmaceuticals$33.99$33.89$17.00▼$39.30$1.63B2.59940,325 shsN/AKNSAKiniksa Pharmaceuticals International$28.09-3.0%$27.71$17.82▼$30.69$2.05B0.05556,024 shs355,269 shsOMEROmeros$3.65+5.5%$3.73$2.95▼$13.60$213.85M2.16735,882 shs954,253 shsPLRXPliant Therapeutics$1.41+0.7%$1.38$1.10▼$16.10$86.56M1.31.20 million shs581,363 shsZGNXZogenix$26.68$26.52$11.03▼$26.90$1.50B0.893.76 million shs94 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNSTConstellation Pharmaceuticals0.00%0.00%0.00%0.00%0.00%KNSAKiniksa Pharmaceuticals International+0.52%+3.93%-2.75%+49.92%+38.12%OMEROmeros+2.37%+8.09%-10.82%-48.59%-14.57%PLRXPliant Therapeutics+2.94%+12.45%-9.09%+4.48%-87.38%ZGNXZogenix0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCNSTConstellation PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AKNSAKiniksa Pharmaceuticals International3.5926 of 5 stars3.54.00.00.02.93.30.6OMEROmeros3.294 of 5 stars3.40.00.04.40.01.70.6PLRXPliant Therapeutics4.5169 of 5 stars3.05.00.04.73.21.70.6ZGNXZogenixN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCNSTConstellation Pharmaceuticals 0.00N/AN/AN/AKNSAKiniksa Pharmaceuticals International 3.00Buy$39.3340.03% UpsideOMEROmeros 2.83Moderate Buy$18.00393.15% UpsidePLRXPliant Therapeutics 2.00Hold$13.31844.15% UpsideZGNXZogenix 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CNST, KNSA, OMER, ZGNX, and PLRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/9/2025KNSAKiniksa Pharmaceuticals InternationalWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$30.00 ➝ $42.006/30/2025OMEROmerosD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.006/27/2025OMEROmerosHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.006/10/2025OMEROmerosHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$9.005/16/2025OMEROmerosNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold5/13/2025OMEROmerosD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.00 ➝ $36.005/7/2025OMEROmerosD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.00 ➝ $36.004/29/2025KNSAKiniksa Pharmaceuticals InternationalJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$40.00 ➝ $45.004/16/2025KNSAKiniksa Pharmaceuticals InternationalWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$34.00 ➝ $34.004/11/2025OMEROmerosD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.00 ➝ $36.00(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCNSTConstellation PharmaceuticalsN/AN/AN/AN/A$8.63 per shareN/AKNSAKiniksa Pharmaceuticals International$423.24M4.84N/AN/A$6.60 per share4.26OMEROmerosN/AN/AN/AN/A($3.15) per shareN/APLRXPliant Therapeutics$1.58M54.78N/AN/A$5.00 per share0.28ZGNXZogenix$81.69M18.36N/AN/A$6.64 per share4.02Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCNSTConstellation Pharmaceuticals-$126.36M-$2.81N/AN/AN/AN/A-33.12%-29.92%N/AKNSAKiniksa Pharmaceuticals International-$43.19M-$0.25N/A112.36N/A-3.52%-3.83%-2.98%7/22/2025 (Estimated)OMEROmeros-$156.82M-$2.65N/AN/AN/AN/AN/A-59.68%8/6/2025 (Estimated)PLRXPliant Therapeutics-$210.30M-$3.61N/AN/AN/AN/A-67.56%-52.54%8/6/2025 (Estimated)ZGNXZogenix-$209.38M-$4.07N/AN/AN/A-278.38%-91.20%-43.60%N/ALatest CNST, KNSA, OMER, ZGNX, and PLRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025OMEROmeros-$0.46N/AN/AN/AN/AN/A8/6/2025Q2 2025PLRXPliant Therapeutics-$0.62N/AN/AN/AN/AN/A7/22/2025Q2 2025KNSAKiniksa Pharmaceuticals International$0.08N/AN/AN/AN/AN/A5/15/2025Q1 2025OMEROmeros-$0.60-$0.65-$0.05-$0.58$0.40 millionN/A4/29/2025Q1 2025KNSAKiniksa Pharmaceuticals International$0.02$0.11+$0.09$0.11$128.35 million$137.79 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCNSTConstellation PharmaceuticalsN/AN/AN/AN/AN/AKNSAKiniksa Pharmaceuticals InternationalN/AN/AN/AN/AN/AOMEROmerosN/AN/AN/AN/AN/APLRXPliant TherapeuticsN/AN/AN/AN/AN/AZGNXZogenixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCNSTConstellation PharmaceuticalsN/A15.3915.39KNSAKiniksa Pharmaceuticals InternationalN/A3.663.43OMEROmerosN/A1.161.16PLRXPliant TherapeuticsN/A11.0311.03ZGNXZogenix0.883.634.74Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCNSTConstellation PharmaceuticalsN/AKNSAKiniksa Pharmaceuticals International53.95%OMEROmeros48.79%PLRXPliant Therapeutics97.30%ZGNXZogenixN/AInsider OwnershipCompanyInsider OwnershipCNSTConstellation Pharmaceuticals43.70%KNSAKiniksa Pharmaceuticals International53.48%OMEROmeros12.90%PLRXPliant Therapeutics8.00%ZGNXZogenix4.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCNSTConstellation Pharmaceuticals15447.92 millionN/ANot OptionableKNSAKiniksa Pharmaceuticals International22072.97 million33.95 millionOptionableOMEROmeros21058.59 million51.04 millionOptionablePLRXPliant Therapeutics9061.39 million56.48 millionOptionableZGNXZogenix21856.23 million53.92 millionOptionableCNST, KNSA, OMER, ZGNX, and PLRX HeadlinesRecent News About These CompaniesAfter epilepsy setback, Zogenix buys Modis and rare disease drug for $400mJanuary 2, 2025 | pharmaphorum.comPNeedle-Free Drug Injection Systems Business Analysis Report 2023-2030 Featuring AKRA Dermojet, Crossject, D`Antonio Consultants, PharmaJet, and ZogenixAugust 1, 2024 | globenewswire.comHwasung Industrial Co Ltd 002460March 23, 2024 | morningstar.comMOrally Inhaled DihydroergotamineFebruary 13, 2024 | medscape.comMMRI in HeadacheAugust 25, 2023 | medscape.comMKratom: What We KnowAugust 13, 2023 | medscape.comMAlcon (NYSE: ALC)July 6, 2023 | fool.comLongeveron Inc Ordinary Shares - Class AMay 20, 2023 | morningstar.comMDravet Syndrome Market Report 2032: Epidemiology Data, Pipeline ... - Digital JournalMay 10, 2023 | news.google.comNGlobal Needle Free Diabetes Management Market Size 2023 ... - The Northwestern ExaminerMay 8, 2023 | news.google.comNGlobal Needle-Free Drug Delivery Systems Market New ... - The Northwestern ExaminerMay 8, 2023 | news.google.comNNeedle Free Injection Systems Market Size Reach Valuation of USD 519.3 Million in 2030 - Emergen Research - openPRMay 4, 2023 | news.google.comNNeedle Free Diabetes Management Market Forecast 2023 – 2032 ... - Taiwan NewsApril 28, 2023 | news.google.comNThe Pathophysiological and Pharmacological Basis of Current Drug Treatment of Migraine HeadacheApril 25, 2023 | medscape.comMLong-Acting Injectable Antipsychotics Market 2023-2033: Global ... - Taiwan NewsApril 24, 2023 | news.google.comNAnti-epileptic Drugs Market Expected to Expand at a Steady 2023 ... - Digital JournalApril 24, 2023 | news.google.comNDravet Syndrome Pipeline Assessment (2023 Updates) | In-depth ... - Digital JournalApril 19, 2023 | news.google.comNForm SC 14D9/A Provention Bio, Inc. Filed by: Provention Bio, Inc. - StreetInsider.comApril 19, 2023 | news.google.comNDEA lifts Dravet therapy Fintepla's controlled substance status |... - Dravet Syndrome NewsApril 18, 2023 | news.google.comNUCB Announces FINTEPLA® (fenfluramine) Oral Solution Is Now ... - Longview News-JournalApril 17, 2023 | news.google.comNNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonTop 3 Bank Stocks to Watch as Fed Rate Cuts LoomBy Chris Markoch | June 25, 2025View Top 3 Bank Stocks to Watch as Fed Rate Cuts Loom3 Cloud Software Leaders Positioned for AI UpsideBy Chris Markoch | July 10, 2025View 3 Cloud Software Leaders Positioned for AI UpsideBroadcom’s Big VMware Update: A Threat to Public Cloud Giants?By Leo Miller | June 28, 2025View Broadcom’s Big VMware Update: A Threat to Public Cloud Giants?GE Aerospace Turns Engines Into Long-Term ProfitsBy Jeffrey Neal Johnson | June 21, 2025View GE Aerospace Turns Engines Into Long-Term ProfitsCNST, KNSA, OMER, ZGNX, and PLRX Company DescriptionsConstellation Pharmaceuticals NASDAQ:CNSTConstellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics to address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include Pelabresib that is in Phase 3 clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib. It is also developing CPI-0209 that is in Phase 1 dose escalation portion of a Phase 1/2 clinical trial to treat solid tumors; and CPI-482, which is in preclinical stage for cancer patients. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. Constellation Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.Kiniksa Pharmaceuticals International NASDAQ:KNSA$28.09 -0.86 (-2.97%) Closing price 04:00 PM EasternExtended Trading$28.23 +0.14 (+0.51%) As of 06:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.Omeros NASDAQ:OMER$3.65 +0.19 (+5.49%) Closing price 04:00 PM EasternExtended Trading$3.68 +0.04 (+0.96%) As of 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.Pliant Therapeutics NASDAQ:PLRX$1.41 +0.01 (+0.71%) Closing price 04:00 PM EasternExtended Trading$1.36 -0.04 (-3.19%) As of 06:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.Zogenix NASDAQ:ZGNXZogenix, Inc. is a pharmaceutical company. The firm engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include Fintepla and MT1621. The company was founded by Stephen James Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. N. Rigby, Scott L. Glenn, and John J. Turanin on May 11, 2006 and is headquartered in Emeryville, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Meteoric Rise of Rocket Lab: A Space Stock to Watch Meta and Autonomous Advertising: The Stock's Next Big Tailwind? Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Chipotle: Too Spicy for Smart Money to Resist After Stock Split Plug Power’s 20% Surge Signals New Commercial Growth Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
